Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (893)	4/14/2000 5:57:00 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

More good news coming out of the EU today. Visudyne recommended for approval by their committee with the Norwegians and Icelandians nodding their heads also. Given the market's reaction to all of this week's outstanding news, I sure hope we quit getting all this good stuff and return to anticipating what's yet to come. ;^) Ian. biz.yahoo.com Friday April 14, 3:01 am Eastern Time Company Press Release SOURCE: CIBA Vision CPMP Recommends Approval in Europe For Visudyne Therapy in the Treatment Of Wet AMD QLT and CIBA Vision Advance to Final Stage of Registration Process in Europe ATLANTA, and VANCOUVER, British Columbia, April 14 /PRNewswire/ -- CIBA Vision, the eye care unit of Novartis, and QLT PhotoTherapeutics Inc. (Nasdaq: QLTI; Toronto) announced today that The Committee for Proprietary Medicinal Products (CPMP) of the European Medicines Evaluation Agency (EMEA) has recommended the granting of a Marketing Authorisation for Visudyne(TM) (verteporfin) therapy for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness among people over the age of 50. The committee unanimously concurred that Visudyne therapy is safe and well-tolerated, with minimal adverse events relating to treatment. The Norwegian and Icelandic CPMP members agreed with the recommendation. The EU Commission is expected to make a final decision regarding the approval of the Visudyne application in the next several months. When approved by the EU Commission, Visudyne therapy will be available throughout the EU, and the Norwegian and Icelandic authorities will grant corresponding national authorizations. ...